Phase II trial of first-line gefitinib in patients unsuitable for chemotherapy with stage III/IV non-small-cell lung cancer
D Swinson, S Williams, K Beddard, L Price… - Journal of Clinical …, 2005 - ascopubs.org
7256 Background: The median age of patients (pts) presenting with non-small-cell lung
cancer (NSCLC) is now> 70 years and the role of chemotherapy in elderly pts with …
cancer (NSCLC) is now> 70 years and the role of chemotherapy in elderly pts with …
Gefitinib for the treatment of non-small-cell lung cancer
T Hida, S Ogawa, JC Park, JY Park… - Expert review of …, 2009 - Taylor & Francis
Gefitinib is an orally bioavailable, EGF receptor tyrosine kinase inhibitor and was the first
targeted drug to be approved for non-small-cell lung cancer (NSCLC). Identification of …
targeted drug to be approved for non-small-cell lung cancer (NSCLC). Identification of …
[引用][C] Comparison of therapeutic efficacy of gefitinib as second-and third-line therapies for patients with non-small cell lung cancer
Z SONG, Y YU, Z CHEN, Y XU, Z LI, S LU - TUMOR, 2011
Gefitinib in advanced non‐small cell lung cancer
R Sharma, M Boyer, S Clarke… - Internal medicine …, 2005 - Wiley Online Library
Background: Gefitinib is an oral, selective epidermal growth factor receptor (EGFR) inhibitor
that has activity in non‐small cell lung cancer (NSCLC). Aim: To evaluate the tolerability …
that has activity in non‐small cell lung cancer (NSCLC). Aim: To evaluate the tolerability …
Efficacy and safety of gefitinib as monotherapy for Chinese patients with advanced non-small cell lung cancer
M Wang, L Li, S Wang, X Zhang, W Zhong… - Chinese medical …, 2006 - journals.lww.com
Patients were eligible for inclusion if they were≥ 18 years with cytology-(except for sputum
cytology)/histopathology-confirmed NSCLC of clinical stages IIIb or IV; who could not …
cytology)/histopathology-confirmed NSCLC of clinical stages IIIb or IV; who could not …
[引用][C] Gefitinib in the Treatment of 16 Patients with Advanced Non-Small-Cell Lung Cancer
Z ZHOU, R LI
[HTML][HTML] Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03
Background Gefitinib is active in patients with pretreated non-small-cell lung cancer
(NSCLC). We evaluated the activity and toxicity of gefitinib first-line treatment in advanced …
(NSCLC). We evaluated the activity and toxicity of gefitinib first-line treatment in advanced …
The role of gefitinib in lung cancer treatment
G Giaccone - Clinical cancer research, 2004 - AACR
Gefitinib (Iressa) is a novel targeted therapy that inhibits the tyrosine kinase activity of the
epidermal growth factor receptor by competitively blocking the ATP binding site. In …
epidermal growth factor receptor by competitively blocking the ATP binding site. In …
Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer
A Argiris, N Mittal - Lung cancer, 2004 - Elsevier
Purpose: To evaluate the efficacy of single-agent gefitinib (Iressa, ZD1839), an oral,
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, as first-line …
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, as first-line …
Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program
R Govindan, R Natale, J Wade, R Herbst, A Krebs… - Lung Cancer, 2006 - Elsevier
Chemotherapy (CT) is recommended in numerous clinical guidelines for advanced non-
small cell lung cancer (NSCLC) and offers improved survival over best supportive care …
small cell lung cancer (NSCLC) and offers improved survival over best supportive care …